← Russell 3000 cross-section

MNKD MANNKIND CORP

Trailing twelve months to 2026-06-30 · as filed 2026-08-05, not restated
Healthcare

Scale

Market cap
$1.3bn
Revenue TTM
$394m
Net income TTM
$-44m
Free cash flow
$-18m
Composite score
35.4
Sector rank
#1877

Valuation

P / E
EV / EBITDA
58.8
EV / sales
3.9
FCF yield
-1.37%
Earnings yield vs 10-yr
-8.03pp

Earnings yield vs 10-yr compares what the business earns per pound invested against the 4.73% a 10-year US Treasury note pays for no equity risk. Negative means you are paying up front for growth not yet delivered.

Quality and growth

Net margin
-11.1%
EBITDA margin
6.6%
ROE
64.9%
ROIC
6.5%
Revenue growth
30.5%

Insider activity, last 90 days

Net open-market
$-0.47m
Buyers
0
Sellers
2

Open-market purchases and sales only. Grants, option exercises, gifts and shares withheld for tax are excluded: they are how people are paid, not what they think.

What management said

RESULTS OF OPERATIONS Trends and Uncertainties Our collaboration agreement with UT entitles us to receive a 10% royalty on net sales of Tyvaso DPI, subject to our sale of a 1% royalty on future net sales to a royalty purchaser (leaving us with a 9% royalty). The decrease was driven primarily by lower demand. The gross-to-net adjustment was 33% of gross revenue, or $8.4 million, for the three months ended June 30, 2026 compared to 32% of gross revenue, or $8.8 million, for the same period in the prior year. As a result, net revenue from sales of Afrezza decreased by $1.3 million, or 7%, for the three months ended June 30, 2026 compared to the same period in the prior year. …MANNKIND CORP, 10-Q, period ended 2026-06-30, filed 2026-08-05

Read the full passage →